A Benign Form of Neuromyelitis Optica Does It Exist? Nicolas Collongues, MD; Philippe Cabre, MD, PhD; Romain Marignier, MD; H?l?ne Z?phir, MD; Caroline Papeix, MD; Bertrand Audoin, MD, PhD; Christine Lebrun-Frenay, MD; Jean Pelletier, MD, PhD; Bertrand Fontaine, MD, PhD; Patrick Vermersch, MD, PhD; Christian Confavreux, MD, PhD; J?r?me de Seze, MD, PhD; Group Members for NOMADMUS and CF-SEP Arch Neurol. ?2011;68(7):918-924
BACKGROUND: Differentiating neuromyelitis optica (NMO) from multiple sclerosis (MS) is a real challenge in the clinical field. In the past, NMO (not MS), was inferred when abnormality was not detected in the brain magnetic resonance imaging (MRI). Recently, some studies have reported abnormalities in the brain MRIs of NMO, but only few among the Asian population.
Background: Acute transverse myelitis (ATM) in patients with no history of central nervous system (CNS) demyelinating disease may be idiopathic or herald the development of neuromyelitis optica spectrum disorder (NMOSD) or multiple sclerosis (MS). NMOSD may differ from MS in pathogenesis, prognosis and response to treatment, and radiological features at the first presentation of ATM that distinguish between NMOSD and MS would be desirable
Objective: To determine anti-AQP4 antibody status in Thai patients with demyelinating diseases. Methods: Blood samples of patients visiting MS clinic at Siriraj Hospital, Thailand were collected and sent to Tohoku University for testing anti-AQP4 antibodies using AQP4-transfected cell-based assay. Diagnosis was as follows
INTRODUCTION: The description of a highly sensitive and specific biomarker for neuromyelitis optica (NMO-IgG/aquaporin-4 antibody) extended the clinical spectrum of NMO to limited forms such as optic neuritis (ON) and longitudinally extensive myelitis (LEM). OBJECTIVE: To asses the sensitivity and specificity of our assay, and to describe the clinical characteristics of the patients who were tested for NMO-IgG. METHODS: NMO-IgG was analysed by immunohistochemistry and confirmed by assay on HEK cells transfected with aquaporin-4.
Brain lesions are not uncommon in neuromyelitis optica (NMO) patients with anti-aquaporin-4 (AQP4) antibody; however, the appearance of these lesions is said to be different from that of those in Western patients with multiple sclerosis (MS). To clarify the similarities and dissimilarities of brain lesions in anti-AQP4 antibody-positive and -negative MS and NMO patients, we examined the presence of anti-AQP4 antibody in the sera of 148 consecutive patients fulfilling Poser’s criteria for clinically definite MS, of whom 38 also met the revised NMO criteria, using an immunofluorescence method, and analyzed brain lesions by magnetic resonance imaging (MRI)
BACKGROUND: Few data exist on a possible benign form of neuromyelitis optica (NMO). OBJECTIVES: To identify NMO with a good outcome (go-NMO) among a large population of patients and to describe demographic and clinical variables associated with go-NMO vs standard NMO and benign multiple sclerosis.
Background: Neuromyelitis Optica (NMO) and its spectrum disorders (NMOSD), which include recurrent transverse myelitis (rTM) and recurrent optic neuritis (rON) are demyelinating diseases of the central nervous system (CNS).
Background: Epidemiological studies have identified ethnicity-based prevalence differences of NMO which is considered to be rare in Caucasians. However, little is actually known about NMO in Caucasians and NMO may be misdiagnosed.
Background: Neuromyelitis optica (NMO) is a rare inflammatory disease. Average age at onset is 35 years
Background: Neuromyelitis optica (NMO) is a rare inflammatory disease. Average age at onset is 35 years. Few data exist on patients with pediatric-onset NMO (p-NMO), with disease onset before age 18 years.
We report 12 aquaporin-4 antibody-positive patients Mayo Clinic patients identifiesince 2005) whose initial presenting symptom of neuromyelitis optica was intractable vomiting. The initialevaluation in 75% was gastroenterologic